The Hidden Dangers of MS Medications: What You Need to Know
Published: Sep 26, 2024
While oral medications for multiple sclerosis can be highly effective, they also carry risks. Understanding these potential dangers is crucial for patients and caregivers.
Contents
Infection Risks
Many MS medications work by suppressing parts of the immune system. This can leave patients more vulnerable to infections, some of which can be serious. For example, progressive multifocal leukoencephalopathy (PML) is a rare but potentially fatal brain infection associated with some MS drugs. Patients may also be at higher risk for common infections like the flu or herpes viruses.
Cardiovascular Concerns
Some oral MS medications, particularly S1PR modulators like fingolimod, can affect heart rhythm. This can cause bradycardia (slow heart rate) or irregular heartbeats, especially when first starting treatment. Patients with pre-existing heart conditions may need extra monitoring or may not be able to take certain drugs. Blood pressure changes are another potential cardiovascular effect to watch for.
Other Organ Effects
MS medications can potentially impact other organs and body systems. Liver injury is a risk with several oral drugs, requiring regular blood tests to monitor liver function. Some medications may affect lung function or vision. For example, macular edema (swelling in the retina) has been associated with fingolimod use. Regular check-ups and screening tests are important to catch any issues early.
Frequently Asked Questions
Serious side effects are generally rare, but minor side effects are more frequent.
Never stop MS medications suddenly without consulting your doctor.
Follow monitoring guidelines and report any new symptoms promptly.
Natural treatments are not necessarily safer and may lack proven efficacy.
Key Takeaways
Understanding medication risks empowers patients to make informed treatment choices and stay vigilant about their health.
Concerned about MS medication risks? Talk to Doctronic about how to balance effectiveness and safety in your treatment plan.Related Articles
References
Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurol Belg 2017; 117:821.
Arvin AM, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72:31.
Always discuss health information with your healthcare provider.